Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odetiglucan + CDX-1140 in Metastatic Pancreatic Adenocarcinoma
NCT05484011Phase 1Terminated
- Sponsor
- HiberCell
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of odetiglucan in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by HiberCell. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Dec 2022; status: terminated.
02
Drugs
odetiglucan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05484011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484011.